

## **Information Governance Department**

Suite 9
Buckingham Row
Brick Kiln Lane
Wigan
WN1 1XX

Email: foi@wwl.nhs.uk Web: www.wwl.nhs.uk

Ref: FOI/2025/10497

Date Received: 4th February 2025

Response Due: 4th March 2025

Date: 4th March 2025

## Dear Sir/Madam

With reference to your request for information received on 4<sup>th</sup> February 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

- 1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
  - Adalimumab Humira = <5.
  - Adalimumab Biosimilar = 204.
  - **Etrasimod** = 0.
  - Filgotinib = <5.
  - **Golimumab** = 0.
  - Infliximab Remicade = 0.
  - Infliximab Biosimilar = 58.
  - Mirikizumab = 9.
  - **Ozanimod** = 0.
  - Risankizumab = 36.
  - Tofacitinib = <5.</li>
  - Upadacitinib = 58.
  - Ustekinumab Stelara = 125.
  - Ustekinumab Biosimilar = 6.
  - Vedolizumab = 66.

The Trust has a standard procedure of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- b) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

## 2. Could you please provide the numbers of patients treated for Crohn's Disease in the last 3 months with the following biologic drugs:

- Adalimumab Humira
- Adalimumab Biosimilars
- Golimumab
- Infliximab Remicade
- Infliximab Biosimilar
- Risankizumab
- Upadacitinib
- Ustekinumab Sterala
- Ustekinumab Biosimilar
- Vedolizumab

	Direct from WWL	Homecare	Off-site provider	Total
Adalimumab - Humira	0	<5	0	<5
Adalimumab Biosimilars	0	140	0	140
Golimumab [Simponi]	0	0	0	0
Infliximab - Remicade	0	0	0	0
Infliximab Biosimilars	?	16	0	16
Risankizumab [Skyrizi]	?	0	0	0
Upadacitinib [Rinvoq]	?	21	?	21
Ustekinumab [Stelara]	?	82	0	82
Ustekinumab [Biosimilar]	?	0	0	0
Vedolizumab [Entyvio]	?	19	0	19

<sup>\*</sup>We only have indication data centrally recorded for homecare patients and so although we can provide total data for the issues of the drugs, we can only provide indication data for that subset. The gaps in the numbers that this creates are indicated by the "?" in boxes in the above table.

In order to obtain the information for those marked with "?", we would have to interrogate individual case notes, as the information is not centrally recorded. As case notes are for the care and treatment of patients, we do not request staff to interrogate them in order to collate the information required to respond to Freedom of Information requests.

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

Gary Masterman Deputy Chief Pharmacist

## PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire, SK9 5AF

Helpline number: 0303 123 111